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Abstract 
Objectives: Individuals with chronic obstructive pulmonary disease (COPD) are usually > 50 years of age and have a 
low body mass index (BMI). An imbalance between matrix metalloproteinases (MMPs), including MMP-3, and tissue 
inhibitor of metalloproteinase 1 (TIMP-1), play a role in tissue degradation of lung extracellular matrix among COPD 
individuals. The purpose of the present study was to correlate age and/or BMI with salivary levels of MMP-3 and 
TIMP-1 among Indonesian subjects with COPD.
Results: Thirty COPD patients were recruited to undergo thorough physical assessment and saliva collection for 
evaluating TIMP-1 and MMP-3 levels using commercially available kits enzyme-linked immunosorbent assay method. 
The mean (standard deviation) participant age and BMI were 60.5 (8.13) years, and 23.1 (4.75) kg/m2, respectively. 
Furthermore, the mean (standard deviation) of TIMP-1 and MMP3 levels were 23.99 (6.85) ng/mL and 1.81 (1.167) 
μM, respectively. Age was negatively correlated with MMP-3 (P < 0.05), but not with TIMP-1 levels. Age and BMI were 
not correlated with TIMP-1 level (P > 0.05). Collectively, this study demonstrated that age has a negative correlation 
with the protease marker (i.e. MMP-3), but not the anti-protease marker (TIMP-1). BMI was not correlated with either 
protease/anti-protease marker among Indonesian subjects with COPD.
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Introduction
The proportion of active smokers with chronic obstruc-
tive pulmonary disease (COPD) is estimated to be 
10–15% [1, 2]. COPD is characterized by partially irre-
versible airflow limitation, emphysema, reduced diam-
eter of the small airways, and chronic bronchitis [3]. 
Smoking cessation may improve symptoms; however, the 
inflammatory process within the airways and in the lung 
parenchyma will persist [4].
Matrix metalloproteinases (MMPs) are counteracted 
by tissue inhibitor of matrix metalloproteinases (TIMPs), 
which results in reduced extracellular matrix (ECM) 
breakdown. The balance between MMPs and TIMPs is 
essential in maintaining the integrity of normal body tis-
sues. An imbalance in the ratio of MMPs and TIMPs may 
manifest as numerous pathological conditions including 
rheumatoid arthritis, cancer, and periodontitis [5].
In the field of periodontology, smoking has been asso-
ciated with an increased incidence and severity of vari-
ous periodontal diseases [6]. Inflammation within the 
oral cavity and in the airway can be assessed using 
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biomarkers. In the case of periodontitis, various tests can 
be performed using samples obtained from saliva and 
gingival crevicular fluid [7, 8].
TIMP-1 inhibits active MMPs, including MMP-1, 
MMP-3, and MMP-9. It has been reported that changes 
in MMP-1 poorly correlated with disease intensity and 
progression in COPD [9]. TIMP-1 binds to pro-MMP-9 
to prevent the activation of pro-MMP-9. However, 
neutrophil elastase acts by dissociating the binding of 
TIMP-1 to pro-MMP-9, which allows MMP-3 to acti-
vate pro-MMP-9 to become MMP-9 [10]. Our previous 
study revealed that salivary MMP-9 was not correlated 
with lung function in COPD patients, which prompted 
us to confirm whether salivary MMP-3 could be a via-
ble biomarker associated with age and body mass index 
(BMI) at the onset of COPD [11]. This study aimed to 
investigate possible correlations between degenerative 
variables, such as age and BMI, and the level of salivary 
MMP-3 and TIMP-1 in Indonesian patients with COPD.
Main text
Methods
This study recruited 30 consecutive smokers with COPD 
who visited the pulmonary outpatient clinic of the Dr. 
Zainoel Abidin General Hospital, located in Banda Aceh, 
Indonesia. The inclusion criteria were a diagnosis of 
COPD; current smoker; male sex; > 50 years of age; and 
20 pack-years of cigarette consumption. Diagnosis of 
COPD was established according to spirometry results 
(i.e., forced expiratory volume in 1  s/forced vital capac-
ity ratio < 70% according to the 2017 Global Initiative 
for Chronic Obstructive Lung Disease guidelines [12]. 
Patients with respiratory or oral infections, or malig-
nancy, were excluded. This study was approved by the 
Ethics Committee of the Faculty of Medicine, University 
of Syiah Kuala, Banda Aceh, Indonesia (Ethical Clearance 
No. 197/KE/FK/2013). All participants were required 
to provide informed consent before undergoing the 
research procedures.
Saliva was collected into sterile pots and stored in 
a − 80  °C freezer for analysis of TIMP-1 and MMP-3 
using a human TIMP-1 quantikine ELISA kit (R&D 
Systems, Minneapolis, MN, USA) and Sensolyte 520 
Generic MMP fluorimetric assay kit (AnaSpec, Fremont, 
CA, USA), respectively, according to manufacturer’s 
protocols.
Data are presented as mean and standard deviation 
(SD). Pearson’s correlation coefficient was used to deter-
mine the correlation between variables. The data were 
analyzed using SPSS version 15.0 (IBM Corporation, 
Chicago, IL, USA) for Windows (Microsoft Corporation, 
Redmond, WA, USA), and P < 0.05 was considered to be 
statistically significant.
Results
The mean (SD) age of the subjects was 60.5 (8.13) years, 
and the mean (SD) BMI was 23.1 (4.75) kg/m2. The mean 
(SD) level of salivary TIMP-1 was 23.99 (6.85) ng/mL, 
and the mean (SD) activity of salivary MMP-3 was 1.81 
(1.167) μM (Table 1).
Next, the authors analyzed the correlation between age 
and BMI with MMP-3 activity using Pearson’s correla-
tion coefficient. Age was significantly correlated with the 
salivary MMP-3 levels (P = 0.002), however BMI was not 
correlated with MMP-3 activity (Table 2).
Finally, the authors investigated possible relationships 
between BMI and anti-protease (i.e., TIMP-1) level using 
Pearson’s correlation coefficient, and found that BMI was 
not correlated with salivary TIMP-1 levels (Table 3).
Discussion
Identification of protease and anti-protease biomark-
ers in COPD patients using non-invasively obtained 
fluid samples are under intensive investigation. It has 
been reported that TIMP-1 levels in lung tissue increase 
in response to higher activities of lung parenchymal 
MMP-3 [13]. In periodontitis, the development of attach-
ment loss will be inhibited by TIMP-1 to prevent further 
potential tissue damage. These are considered to be the 
natural responses of anti-proteases against increased 
protease activity [14].
MMPs are divided into several subgroups according 
to their primary substrate, such as collagenases (MMP-1 
and MMP-13) degrading the interstitial collagens, and 
gelatinases (MMP-2 and MMP-9) that degrade basal 
membrane components such as fibronectin and elas-
tin [15]. As an “anti-protease”, TIMP-1 acts in response 
to increased activities of MMP-3 and MMP-9, and acts 
to prevent degradation of ECM in tissues. If there is 
reduced ability of TIMP to act against exogenous and 
endogenous MMP, this will result in the prolonged and 
increased activity of MMP-3 and MMP-9, which results 
in ECM damage [16, 17].
MMP-3 is a broad-spectrum MMP that functions by 
activating latent MMPs including pro-MMP-1, -8 and 
-9. The overall cascade of tissue degradation occurs due 
to the involvement of the regulatory effects of MMP-3 
Table 1 Subject characteristics
MMP-3 matrix metalloproteinase-3, TIMP-1 tissue inhibitor of metalloproteinase 1
Variable Mean (SD)
Age (years) 60.5 (8.13)
Body mass index (kg/m2) 23.1 (4.75)
MMP-3 activity (µM) 1.81 (1.167)
TIMP-1 level (ng/mL) 23.99 (6.85)
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both physiologically and pathologically. The expression 
of MMP-3 and increased amounts of MMP-3 messen-
ger RNA in periodontal lesions have been reported in 
previous studies, which concluded that MMP-3 may be 
marker for assessing the tissue degradation process [5].
There is an increased risk for periodontitis among 
smokers with COPD. In contrast, smokers without 
COPD exhibit higher mean TIMP-1 levels in response 
to increased activities of MMP-3 and MMP-9. Verstap-
pen et  al. [18] observed increased levels of TIMP-1 in 
the healthy periodontium compared with inflamed peri-
odontium, which represents a homeostatic mechanism to 
sustain balances between proteases and anti-proteases to 
prevent ECM damage.
TIMP-1 is crucial to the balance of increased MMP-9 
activity, and cigarette smoke exposure among smokers 
without COPD could be implicated in the activation of 
several pro-inflammatory signally pathways, including 
oxidative stress, pro-inflammatory cells, and alveolar 
macrophages, which results in the activation of several 
proteases, especially MMP-9. An in vivo study reported 
that TIMP-1 was highly expressed in respiratory epithe-
lial cells that had been exposed to chronic inflamma-
tion. The epithelial tissue expressed TIMP-1 in response 
to the activity of MMPs [19]. Furthermore, in a study 
by Higashimoto et  al. [20], involving smokers without 
COPD who consumed the same number of cigarettes as 
smokers with COPD, suggested a similar risk for continu-
ous airway inflammation between both groups and due 
to persistent cigarette smoke exposure.
Fujita [21] found that the activities of both MMP-9 
and TIMP-1 following lung injury in COPD led to either 
recovery or degradation of ECM. Among smokers with-
out COPD, the activities of MMP-9 and TIMP-1 will 
result in recovery and resolution; meanwhile, in smok-
ers with COPD, this will result in ECM destruction and 
emphysema [21].
In conclusion, our preliminary findings suggest that 
salivary TIMP-1 is not a suitable biomarker in Indonesian 
subjects with COPD. There was, however, a significant 
negative correlation between age and the level of MMP-3 
activity. Further study with a more heterogeneous popu-
lation is required to clarify the precise role of TIMP-1 as 
a possible biomarker of anti-protease activity in the lung.
Limitations
The current study involved a small number of subjects; 
therefore, the findings may not reflect the true corre-
lation that may exist between protease/anti-protease 
imbalances and age and BMI. Furthermore, the study was 
conducted in a single-institution and involved only male 
subjects, which, considering the heterogeneity of the 
Indonesian population, may restrict the generalizability 
of the findings.
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